Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Status:
Recruiting
Trial end date:
2025-12-05
Target enrollment:
Participant gender:
Summary
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of
prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in
subjects with metastatic castration-resistant prostate cancer, and to determine the maximum
tolerated dose (MTD) or recommended phase 2 dose (RP2D).